149 related articles for article (PubMed ID: 11722411)
1. Prolonged molecular remission in advanced acute promyelocytic leukaemia after treatment with gemtuzumab ozogamicin (Mylotarg CMA-676).
Petti MC; Pinazzi MB; Diverio D; Romano A; Petrucci MT; De Santis S; Meloni G; Tafuri A; Mandelli F; Lo Coco F
Br J Haematol; 2001 Oct; 115(1):63-5. PubMed ID: 11722411
[TBL] [Abstract][Full Text] [Related]
2. Extramedullary relapse in a patient with acute promyelocytic leukemia: successful treatment with arsenic trioxide, all-trans retinoic acid and gemtuzumab ozogamicin therapies.
Tsimberidou AM; Estey E; Whitman GJ; Dryden MJ; Ratnam S; Pierce S; Faderl S; Giles F; Kantarjian HM; Garcia-Manero G
Leuk Res; 2004 Sep; 28(9):991-4. PubMed ID: 15234578
[TBL] [Abstract][Full Text] [Related]
3. Gemtuzumab ozogamicin: promise and challenge in patients with acute myeloid leukemia.
Giles FJ
Expert Rev Anticancer Ther; 2002 Dec; 2(6):630-40. PubMed ID: 12503209
[TBL] [Abstract][Full Text] [Related]
4. Prolonged molecular remission in a newly diagnosed acute promyelocytic leukaemia with a severe cardiomyopathy using low-dose gemtuzumab ozogamicin and all-trans retinoic acid.
Martini V; Minotti C; Breccia M; De Angelis G; Buffolino S; Mariella M; Lo-Coco F; Avvisati G; Cimino G
Ann Hematol; 2007 Apr; 86(4):295-7. PubMed ID: 17136541
[No Abstract] [Full Text] [Related]
5. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukaemia in first relapse.
Sievers EL
Expert Opin Biol Ther; 2001 Sep; 1(5):893-901. PubMed ID: 11728223
[TBL] [Abstract][Full Text] [Related]
6. Treatment of relapsed or refractory acute promyelocytic leukemia.
Tallman MS
Best Pract Res Clin Haematol; 2007 Mar; 20(1):57-65. PubMed ID: 17336255
[TBL] [Abstract][Full Text] [Related]
7. Treatment of acute promyelocytic leukemia with gemtuzumab ozogamicin.
Lo Coco F; Ammatuna E; Noguera N
Clin Adv Hematol Oncol; 2006 Jan; 4(1):57-62, 76-7. PubMed ID: 16562371
[TBL] [Abstract][Full Text] [Related]
8. Gemtuzumab Ozogamicin Followed by Unrelated Cord Blood Transplantation With Reduced-intensity Conditioning for a Child With Refractory Acute Promyelocytic Leukemia.
Yamada Y; Osumi T; Kato M; Shioda Y; Kiyotani C; Terashima K; Hayakawa A; Iijima-Yamashita Y; Horibe K; Matsumoto K; Tomizawa D
J Pediatr Hematol Oncol; 2022 May; 44(4):178-180. PubMed ID: 35091516
[TBL] [Abstract][Full Text] [Related]
9. Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial.
Burnett AK; Russell NH; Hills RK; Bowen D; Kell J; Knapper S; Morgan YG; Lok J; Grech A; Jones G; Khwaja A; Friis L; McMullin MF; Hunter A; Clark RE; Grimwade D;
Lancet Oncol; 2015 Oct; 16(13):1295-305. PubMed ID: 26384238
[TBL] [Abstract][Full Text] [Related]
10. Management of acute promyelocytic leukemia.
Tallman MS; Nabhan C
Curr Oncol Rep; 2002 Sep; 4(5):381-9. PubMed ID: 12162911
[TBL] [Abstract][Full Text] [Related]
11. Combination therapy with arsenic trioxide, all-trans retinoic acid, and gemtuzumab ozogamicin in recurrent acute promyelocytic leukemia.
Aribi A; Kantarjian HM; Estey EH; Koller CA; Thomas DA; Kornblau SM; Faderl SH; Laddie NM; Garcia-Manero G; Cortes JE
Cancer; 2007 Apr; 109(7):1355-9. PubMed ID: 17326049
[TBL] [Abstract][Full Text] [Related]
12. Successful induction of molecular remission with single-agent anti-CD33 antibody (gemtuzumab ozogamicin) in chemotherapy-refractory relapse of acute myeloid leukaemia post-BMT.
Swords R; Hayden PJ; Molloy K; Lawlor M; Browne PV; Murphy PT
Eur J Haematol; 2004 Dec; 73(6):450-1. PubMed ID: 15522070
[No Abstract] [Full Text] [Related]
13. Use of arsenic trioxide in remission induction and consolidation therapy for acute promyelocytic leukaemia in the Australasian Leukaemia and Lymphoma Group (ALLG) APML4 study: a non-randomised phase 2 trial.
Iland HJ; Collins M; Bradstock K; Supple SG; Catalano A; Hertzberg M; Browett P; Grigg A; Firkin F; Campbell LJ; Hugman A; Reynolds J; Di Iulio J; Tiley C; Taylor K; Filshie R; Seldon M; Taper J; Szer J; Moore J; Bashford J; Seymour JF;
Lancet Haematol; 2015 Sep; 2(9):e357-66. PubMed ID: 26685769
[TBL] [Abstract][Full Text] [Related]
14. Acute promyelocytic leukemia: what are the treatment options?
Ferrara F
Expert Opin Pharmacother; 2010 Mar; 11(4):587-96. PubMed ID: 20163270
[TBL] [Abstract][Full Text] [Related]
15. [Molecular remission induced by gemtuzumab ozogamicin in an elderly patient with relapsed acute promyelocytic leukemia].
Yago K; Aono M; Shimada H
Rinsho Ketsueki; 2010 Apr; 51(4):286-90. PubMed ID: 20467227
[TBL] [Abstract][Full Text] [Related]
16. Molecular remission induction with retinoic acid and anti-CD33 monoclonal antibody HuM195 in acute promyelocytic leukemia.
Jurcic JG; DeBlasio T; Dumont L; Yao TJ; Scheinberg DA
Clin Cancer Res; 2000 Feb; 6(2):372-80. PubMed ID: 10690513
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse.
Sievers EL; Larson RA; Stadtmauer EA; Estey E; Löwenberg B; Dombret H; Karanes C; Theobald M; Bennett JM; Sherman ML; Berger MS; Eten CB; Loken MR; van Dongen JJ; Bernstein ID; Appelbaum FR;
J Clin Oncol; 2001 Jul; 19(13):3244-54. PubMed ID: 11432892
[TBL] [Abstract][Full Text] [Related]
18. Optimizing treatment for elderly patients with acute promyelocytic leukemia: is it time to replace chemotherapy with all-trans retinoic acid and arsenic trioxide?
Tsimberidou AM; Kantarjian H; Keating MJ; Estey E
Leuk Lymphoma; 2006 Nov; 47(11):2282-8. PubMed ID: 17107899
[TBL] [Abstract][Full Text] [Related]
19. Successful treatment with gemtuzumab ozogamicin monotherapy in a pediatric patient with resistant relapse of acute myeloid leukemia.
Unal S; Cakir M; Kuşkonmaz B; Cetin M; Tuncer AM
Turk J Pediatr; 2009; 51(1):69-71. PubMed ID: 19378895
[TBL] [Abstract][Full Text] [Related]
20. Gemtuzumab ozogamicin.
McGavin JK; Spencer CM
Drugs; 2001; 61(9):1317-22; discussion 1323-4. PubMed ID: 11511025
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
